Logo image
Cost-effectiveness and budget impact of topical antimicrobial polyhexamethylene biguanide with a surfactant betaine on wound bed preparation in venous leg ulcers: An analysis in Australia from a community perspective
Journal article

Cost-effectiveness and budget impact of topical antimicrobial polyhexamethylene biguanide with a surfactant betaine on wound bed preparation in venous leg ulcers: An analysis in Australia from a community perspective

Pinaki Ghosh, Alison Vallejo and Sumita Poopalalingam
Wounds International, Vol.17(1), pp.12-18
2026
url
https://woundsinternational.com/wp-content/uploads/2026/04/WINT_17-1_12-18_Ghosh_v4.pdfView
Published Version Open

Abstract

Anti-infective agents Cost-effectiveness analysis QALYs Venous leg ulcers Wound healing
Background and aim: Venous leg ulcers (VLUs) constitute 60–80% of leg ulcerations, often becoming chronic and imposing significant economic burdens, with Australia spending more than AUD$3 billion annually on chronic wound care. This study evaluates the cost-effectiveness and budget impact of Prontosan Solution (PS), a biofilm-disrupting and cleansing agent, compared to standard saline solution for treating chronic VLUs from an Australian healthcare perspective. Methods: A Markov model was developed in MS Excel to simulate 1-year costs and health-related quality of life (QALYs) for VLU patients treated with PS versus saline. The model used monthly cycles, incorporating clinical parameters from European studies, deemed applicable to Australia. Costs included routine care and complications, derived from Australian literature. Probabilistic sensitivity analysis (PSA) assessed parameter uncertainty, and the model was validated using unpublished randomised controlled trial (RCT) data and expert input. Results: PS yielded 0.0087 additional QALYs and cost savings of $295.23 per patient compared to saline. PSA indicated a 98.80% probability of PS being cost-effective at a $25,000 WTP threshold. For 121,834 annual VLU cases, PS could save approximately $35,969,051.82, or $17,984,525.91 for non-healing wounds. Conclusion: PS is cost-effective and cost-saving compared to saline for VLU treatment, offering improved patient outcomes and substantial budget impact in Australia.

Details

Metrics

1 Record Views
Logo image